{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T14:30:04Z","timestamp":1760711404497,"version":"3.28.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"22","license":[{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Health-system pharmacists play a crucial role in monitoring the pharmaceutical pipeline to manage formularies, allocate resources, and optimize clinical programs for new therapies. This article aims to support pharmacists by sharing new and anticipated novel drug approvals.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>Selected drug approvals anticipated in the 12-month period covering the third quarter of 2024 through the second quarter of 2025 are reviewed. The analysis emphasizes drugs expected to have significant clinical and financial impact in hospitals and clinics selected from 54 novel drugs awaiting US Food and Drug Administration approval. New cell therapies for treating cancers continue to enter the drug pipeline, while novel targeted therapies for biliary tract, gastric, pancreatic, and breast cancers, as well as 3 subcutaneous versions of already approved drugs given intravenously, are awaiting approval. Additionally, many novel drugs are being developed for treatment of rare and ultra-rare diseases such as hereditary angioedema, macular telangiectasia, congenital adrenal hyperplasia, and Barth syndrome. Two new subcutaneous drugs for hemophilia, a new oral medication for hereditary angioedema, a novel monoclonal antibody for atopic dermatitis, and the first oral penem antibiotic are also in the pipeline.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>New drugs with various indications for cancers and rare diseases continue to strengthen the drug pipeline.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxae242","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T14:32:45Z","timestamp":1724855565000},"page":"1103-1108","source":"Crossref","is-referenced-by-count":5,"title":["Recent and anticipated novel drug approvals (3Q 2024 through 2Q 2025)"],"prefix":"10.1093","volume":"81","author":[{"given":"Matthew H","family":"Rim","sequence":"first","affiliation":[{"name":"Northwestern Medicine , Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Collin","family":"Dean","sequence":"additional","affiliation":[{"name":"Northwestern Medicine , Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enela","family":"Aliaj","sequence":"additional","affiliation":[{"name":"Northwestern Medicine , Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany L","family":"Karas","sequence":"additional","affiliation":[{"name":"Northwestern Medicine , Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farah","family":"Barada","sequence":"additional","affiliation":[{"name":"Northwestern Medicine , Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M","family":"Levitsky","sequence":"additional","affiliation":[{"name":"IPD Analytics , Aventura, FL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"article-title":"IPD Analytics","year":"2023","author":"Brand and Biosimilar Pipeline Database [proprietary data]","key":"2024110802453874700_CIT0001"},{"key":"2024110802453874700_CIT0002","article-title":"Recent and anticipated novel drug approvals (Q2 2024 through Q1 2025)","author":"Rim","year":"2024","journal-title":"Am J Health-Syst Pharm"},{"year":"2024","author":"US Food and Drug Administration","key":"2024110802453874700_CIT0003"},{"author":"US Food and Drug Administration","key":"2024110802453874700_CIT0004"},{"year":"2024","author":"Novo Nordisk A\/S","key":"2024110802453874700_CIT0005"},{"year":"2024","author":"Rocket Pharmaceuticals, Inc","key":"2024110802453874700_CIT0006"},{"year":"2024","author":"OncLive","key":"2024110802453874700_CIT0007"},{"year":"2024","author":"Merck & Co., Inc","key":"2024110802453874700_CIT0008"},{"issue":"3","key":"2024110802453874700_CIT0009","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S1470-2045(23)00649-6","article-title":"TAbelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein\u2013Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial","volume":"25","author":"Mahadeo","year":"2024","journal-title":"Lancet Oncol"},{"issue":"16 suppl","key":"2024110802453874700_CIT0010","article-title":"Results from the pivotal phase (PH) 2b HERIZON-BTC-01 study: zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC)","volume":"41","author":"Pant","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10389","key":"2024110802453874700_CIT0011","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-esophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomized, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"2024110802453874700_CIT0012","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcnima: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nature Medicine"},{"issue":"16","key":"2024110802453874700_CIT0013","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2217\/fon-2023-0824","article-title":"The phase I\/II eNRGy trial: zenocutuzumab in patients with cancers harboring NRG1 gene fusions","volume":"20","author":"Kim","year":"2024","journal-title":"Future Oncol"},{"issue":"16 suppl","key":"2024110802453874700_CIT0014","doi-asserted-by":"crossref","first-page":"abstract 1003","DOI":"10.1200\/JCO.2024.42.16_suppl.1003","article-title":"First-line inovolisib\/placebo + plabociclib + fulvestrant (Inavo\/Pbo+Palbo+Fulv) in patietns (pts) with PIK3CA-mutated, hormone receptor-poistive, HER2-negative locally advanced\/metastatic breast cancer who relapsed during\/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 phase III randomized trial additional analyses","volume":"42","author":"Juric","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"2024110802453874700_CIT0015","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.annonc.2023.05.009","article-title":"IMscin001 part 2: a randomized phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications","volume":"34","author":"Burotto","year":"2023","journal-title":"Ann Oncol"},{"issue":"4 suppl","key":"2024110802453874700_CIT0016","article-title":"Subcutaneous nivolumab (Nivo SC) vs intravenous nivolumab (Nivo IV) in patients with previously treated advanced or metastatic clear cell renal cell carcnimona (ccRCC): pharamacokinetics (PK), efficacy, and safety results from CheckMate 67T","volume":"42","author":"George","year":"2024","journal-title":"J Clin Oncol"},{"issue":"17 suppl","key":"2024110802453874700_CIT0017","doi-asserted-by":"crossref","first-page":"abstract LBA8505","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8505","article-title":"Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial","volume":"42","author":"Leighl","year":"2024","journal-title":"J Clin Oncol"},{"year":"2023","author":"Pfizer Inc","key":"2024110802453874700_CIT0018"},{"year":"2024","author":"Sanofi","key":"2024110802453874700_CIT0019"},{"issue":"1","key":"2024110802453874700_CIT0020","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa2314192","article-title":"Oral sebetralstat for on-demand treatment of hereditay angioedema attacks","volume":"391","author":"Riedl","year":"2024","journal-title":"N Engl J Med"},{"author":"Neurotech Pharmaceuticals, Inc","key":"2024110802453874700_CIT0021"},{"year":"2024","author":"Healio","key":"2024110802453874700_CIT0022"},{"year":"2024","author":"Eli Lilly and Company","key":"2024110802453874700_CIT0023"},{"year":"2024","author":"Neurocrine Biosciences, Inc","key":"2024110802453874700_CIT0024"},{"year":"2024","author":"Stealth BioTherapeutics Inc","key":"2024110802453874700_CIT0025"},{"issue":"7","key":"2024110802453874700_CIT0026","doi-asserted-by":"crossref","first-page":"101138","DOI":"10.1016\/j.gim.2024.101138","article-title":"Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER","volume":"26","author":"Thompson","year":"2024","journal-title":"Genet Med"},{"author":"Iterum Therapeutics","key":"2024110802453874700_CIT0027"},{"year":"2024","author":"Iterum Therapeutics","key":"2024110802453874700_CIT0028"},{"year":"2024","author":"Vertex","key":"2024110802453874700_CIT0029"},{"author":"Ionis","key":"2024110802453874700_CIT0030"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxae242\/59830962\/zxae242.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/81\/22\/1103\/60500455\/zxae242.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/81\/22\/1103\/60500455\/zxae242.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T02:45:47Z","timestamp":1731033947000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/81\/22\/1103\/7743135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":30,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2024,8,28]]},"published-print":{"date-parts":[[2024,11,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxae242","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"type":"print","value":"1079-2082"},{"type":"electronic","value":"1535-2900"}],"subject":[],"published-other":{"date-parts":[[2024,11,15]]},"published":{"date-parts":[[2024,8,28]]}}}